4-氨基-2-乙氧基苯甲酸甲酯 | 2486-55-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氨基-2-乙氧基苯甲酸甲酯
• 英文名称: methyl 4-amino-2-ethoxybenzoate
• CAS: 2486-55-7
• 化学式: C₁₀H₁₃NO₃
• 分子量: 195.218
• InChiKey: PKWWPNQVVNPGPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-氨基-2-乙氧基苯甲酸甲酯 在 盐酸 、 sodium hydroxide 、 氯化亚砜 、 phosphorus pentoxide 、 三乙胺 、 sodium nitrite 作用下， 以 辛醇 、 乙醇 、 二氯甲烷 、 水 、 xylene 为溶剂， 反应 81.0h， 生成 4-(5,6-dichloro-1H-benzimidazol-2yl)-3-ethoxy-N-(2,2,6,6-tetramethyl-piperidin-4yl)-benzamide
  参考文献：
  名称：

  Synthesis of photoactivable inhibitors of osteoclast vacuolar ATPase

  摘要：

  Amides of (2Z,4E)-5-[(5,6-dichloroindol-2-yl)]-2-methoxy-N-[3-[4-[3-(carboxymethoxy)phenyl)] piperazin-1-yl]propyl]-2,4-pentadienamide (1) and of 5-(5,6-dichloro-2-indolyl)-2-methoxy-2,4-pentadienoic acid (2) are strong inhibitors of the vacuolar ATPase located on the plasma membrane of osteoclasts. In order to understand which V-ATPase subunit is involved in the interaction with these novel inhibitors, analogues containing a photoactivable group and an iodine atom were designed. A series of alcohols or amines containing the photoactivable trifluoroaziridinophenyl or benzophenone moiety and an iodine atom were linked to the above acids via an ester or amide group. These compounds could be thereafter used as a radioactive photoprobe to label the protein. Whereas the compounds containing the photoactivable groups maintained good inhibitory activity, the introduction of the bulky iodine atom was generally detrimental, decreasing potency significantly. Better results were obtained by linking. 3-(4-amino-piperidinomethyl)-3'-iodobenzophenone to 3-ethoxy-4-(2-(5,6-dichlorobenzimidazolyl))benzoic acid to give the corresponding amide 27, that inhibited vacuolar ATP-ase with a IC50 = 140 nM. The feasibility of introducing a radioactive 1211 atom,was ascertained by exchanging the iodine with a tributylstannyl group, that was again substituted by iodine. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00106-8
• 作为产物：
  描述：

  2-乙氧基-4-硝基苯甲酸 在 硫酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 2.5h， 生成 4-氨基-2-乙氧基苯甲酸甲酯
  参考文献：
  名称：

  [EN] MODIFIED PROTEINS AND PROTEIN DEGRADERS
  [FR] PROTÉINES MODIFIÉES ET AGENTS DE DÉGRADATION DE PROTÉINES

  摘要：

  本文提供了结合或降解靶蛋白的化合物、药物组合物和方法。本文还提供了具有DNA损伤结合蛋白1（DDB1）结合基团的化合物。其中一些实施例包括连接物。其中一些实施例包括靶蛋白结合基团。本文还提供了配体-DDB1复合物。本文还提供了体内修饰的DDB1蛋白。

  公开号：

  WO2021239117A1

文献信息

• New compounds
  申请人：Zahn Stephan Karl

  公开号：US20090163467A1

  公开（公告）日：2009-06-25

  The present invention encompasses compounds of general formula (1) wherein R 1 , R 2 , R 4 , X, m, n and p are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.

  本发明涵盖了一般式（1）的化合物 其中 R 1 ，R 2 ，R 4 ，X，m，n和p的定义如权利要求书中所述 ，适用于治疗以细胞过度或异常增殖为特征的疾病，并且用于制备具有上述特性的药物组合物。
• [EN] SSTR5 ANTAGONISTS<br/>[FR] ANTAGONISTES DE SSTR5
  申请人：KALLYOPE INC

  公开号：WO2021113368A1

  公开（公告）日：2021-06-10

  This disclosure is directed, at least in part, to SSTR5 antagonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the SSTR5 antagonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

  这项披露至少部分针对SSTR5拮抗剂，用于治疗涉及肠脑轴的疾病或疾病。在某些实施例中，SSTR5拮抗剂是肠限制性化合物。在某些实施例中，该疾病或疾病是代谢性疾病，如糖尿病、肥胖症、非酒精性脂肪肝炎（NASH）或营养紊乱，如短肠综合征。
• Substituted Pyrrolidine-2-Carboxamides
  申请人：Bartkovitz David Joseph

  公开号：US20100152190A1

  公开（公告）日：2010-06-17

  There are provided compounds of the formula wherein X, Y, R 1 , R 2 , R 3 , R 3 , R 4 , R 5 , R 6 and R 7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

  提供了以下公式的化合物，其中X、Y、R1、R2、R3、R4、R5、R6和R7如本文所述，并且其对映体和药学上可接受的盐和酯。这些化合物可用作抗癌剂。
• Substituted pyrrolidine-2-carboxamides
  申请人：Bartkovitz David Joseph

  公开号：US08354444B2

  公开（公告）日：2013-01-15

  There are provided compounds of the formula wherein X, Y, R1, R2, R3, R3, R4, R5, R6 and R7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

  提供了以下式子的化合物：其中X，Y，R1，R2，R3，R3，R4，R5，R6和R7的描述如下，并提供其对映异构体和药学上可接受的盐和酯。这些化合物可用作抗癌剂。
• Synthesis and evaluation of novel serotonin 4 receptor radiotracers for single photon emission computed tomography
  作者：Julien Lalut、Benjamin B. Tournier、Thomas Cailly、Cédric Lecoutey、Sophie Corvaisier、Audrey Davis、Céline Ballandonne、Marc Since、Philippe Millet、Frédéric Fabis、Patrick Dallemagne、Christophe Rochais

  DOI：10.1016/j.ejmech.2016.03.059

  日期：2016.6

  Despite its implication in several physiological and pathological processes the serotonin subtype-4 receptor (5-HT4R) has seen limited effort for the development of radiolabeling agent especially concerning single photon emission computed tomography (SPECT). Bearing an ester function, the available ligands are rapidly susceptible to hydrolysis which limits their use in vivo. In this study the synthesis of iodinated benzamide and ketone analogs were described. Their affinity for the 5-HT4R and their lipophilicity were evaluated and the most promising derivatives were evaluated ex vivo for their binding to the receptor and for their ability to displace the reference ligand [I-125]-SB207710. (C) 2016 Elsevier Masson SAS. All rights reserved.